Search research articles
Contact Us
Filters
Showing results (1-10 of 14) with videos related to
Page
of 2
Sort By:
Translational Lung Cancer Research
|
March 26, 2015
Immunotherapy in lung cancer
Liza C Villaruz, Aparna Kalyan, Hassane Zarour, et al.
CA: a Cancer Journal for Clinicians
|
May 12, 2012
Immunotherapy of cancer in 2012
John M Kirkwood, Lisa H Butterfield, Ahmad A Tarhini, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
December 10, 2002
HLA-DP4, the most frequent HLA II molecule, defines a new supertype of peptide-binding specificity
Florence A Castelli, Cécile Buhot, Alain Sanson, et al.
Melanoma Research
|
February 22, 2023
Screening costs associated with donor selection for fecal microbiota transplantation for treatment of PD-1 refractory melanoma patients
Dylan Fortman, Maria G Pazan Avellan, Drew Hurd, et al.
Journal for Immunotherapy of Cancer
|
July 13, 2018
Perspectives in immunotherapy: meeting report from the Immunotherapy Bridge (29-30 November, 2017, Naples, Italy)
Paolo A Ascierto, James Brugarolas, Luigi Buonaguro, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 29, 2017
Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma
Caroline Robert, Antoni Ribas, Omid Hamid, et al.
Journal for Immunotherapy of Cancer
|
December 1, 2019
Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge 2018" (28-29 November, 2018, Naples, Italy)
Paolo A Ascierto, Carlo Bifulco, Luigi Buonaguro, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 19, 2016
Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma
Adil I Daud, Jedd D Wolchok, Caroline Robert, et al.
Journal of Translational Medicine
|
November 18, 2017
Future perspectives in melanoma research "Melanoma Bridge", Napoli, November 30th-3rd December 2016
Paolo A Ascierto, Sanjiv S Agarwala, Gennaro Ciliberto, et al.
Lancet (London, England)
|
July 19, 2014
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
Caroline Robert, Antoni Ribas, Jedd D Wolchok, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 14) with videos related to
Sort By:
Page
of 2
Translational Lung Cancer Research
|
March 26, 2015
Immunotherapy in lung cancer
Liza C Villaruz, Aparna Kalyan, Hassane Zarour, et al.
CA: a Cancer Journal for Clinicians
|
May 12, 2012
Immunotherapy of cancer in 2012
John M Kirkwood, Lisa H Butterfield, Ahmad A Tarhini, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
December 10, 2002
HLA-DP4, the most frequent HLA II molecule, defines a new supertype of peptide-binding specificity
Florence A Castelli, Cécile Buhot, Alain Sanson, et al.
Melanoma Research
|
February 22, 2023
Screening costs associated with donor selection for fecal microbiota transplantation for treatment of PD-1 refractory melanoma patients
Dylan Fortman, Maria G Pazan Avellan, Drew Hurd, et al.
Journal for Immunotherapy of Cancer
|
July 13, 2018
Perspectives in immunotherapy: meeting report from the Immunotherapy Bridge (29-30 November, 2017, Naples, Italy)
Paolo A Ascierto, James Brugarolas, Luigi Buonaguro, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 29, 2017
Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma
Caroline Robert, Antoni Ribas, Omid Hamid, et al.
Journal for Immunotherapy of Cancer
|
December 1, 2019
Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge 2018" (28-29 November, 2018, Naples, Italy)
Paolo A Ascierto, Carlo Bifulco, Luigi Buonaguro, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 19, 2016
Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma
Adil I Daud, Jedd D Wolchok, Caroline Robert, et al.
Journal of Translational Medicine
|
November 18, 2017
Future perspectives in melanoma research "Melanoma Bridge", Napoli, November 30th-3rd December 2016
Paolo A Ascierto, Sanjiv S Agarwala, Gennaro Ciliberto, et al.
Lancet (London, England)
|
July 19, 2014
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
Caroline Robert, Antoni Ribas, Jedd D Wolchok, et al.
Page
of 2